0001193125-26-210463
SEC filingPalvella's Q1 2026 net loss widened to $15.8M from $8.2M, driven by increased R&D and G&A costs as the company advances its clinical pipeline and builds public company infrastructure.
Research and development expenses increased significantly in the first quarter of 2026 compared to the prior year period. The increase was primarily driven by costs associated with advancing the QTORIN rapamycin programs, including clinical trial activities, chemistry, manufacturing and controls (CMC) work, and higher headcount. As product candidates move into later stages of clinical development, costs generally increase due to larger and longer trials. The company expects R&D expenses to continue to rise as it prepares for a pre-NDA meeting with the FDA for QTORIN rapamycin in microcystic lymphatic malformations and plans to initiate a Phase 3 pivotal study for cutaneous venous malformations.
General and administrative expenses increased compared to the prior year period. The increase was primarily due to higher headcount in 2026 and increased professional services costs related to operating as a publicly-traded company. Management anticipates that G&A expenses will increase substantially in the future as the organization grows to support commercialization and other public company requirements.
Net loss for the first quarter of 2026 was $15.8 million, compared to $8.2 million in the same period last year. The increase in net loss was driven by higher operating expenses, partially offset by an increase in interest income due to higher average balances in interest-bearing cash and money market funds. Diluted earnings per share were -$1.20, compared to -$0.74 in the prior year period, reflecting both the higher net loss and an increased share count from the February 2026 equity offering.
Net cash used in operating activities was $10.9 million in the first quarter of 2026, compared to $6.8 million in the prior year period, reflecting higher operating expenses and changes in working capital. The company has funded its operations primarily through proceeds from the Amended Ligand Agreement and sales of debt and equity securities. Management may seek additional capital based on market conditions or strategic considerations, even if current funds are deemed sufficient for near-term plans.
Palvella is approaching a pivotal regulatory milestone: a pre-NDA meeting with the FDA for QTORIN rapamycin in microcystic LMs is expected in Q2 2026, with an NDA submission anticipated thereafter. The company also plans to initiate a Phase 3 pivotal study for cutaneous venous malformations in the second half of 2026. These catalysts will drive further increases in R&D spending. Management expects G&A expenses to rise as the organization grows to support commercialization. The company's ability to execute on these milestones while managing cash burn will be critical for investors to monitor.